The TP53 Arg72Pro polymorphism and lung cancer risk in a population of Northern Spain

Lung Cancer

Volumn 61, Issue 3, 2008, Pages 309-316

  Fernández Rubio, Aida ^a   López Cima, M Felicitas ^a   González Arriaga, Patricia ^a   García Castro, Laura ^a   Pascual, Teresa ^b   Marrón, Manuel G ^b   Tardón, Adonina ^a  

^a Faculty de Medicina   (Spain)

^b HOSPITAL DE CABUEÑES   (Spain)

Author keywords

Lung cancer risk; Molecular epidemiology; Polymorphism; TP53; Tumor suppressor gene

Indexed keywords

ARGININE; PROLINE; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CIGARETTE SMOKING; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENOTYPE; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING HABIT; SPAIN;

CARCINOMA, SMALL CELL; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENES, P53; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK; SMOKING; SPAIN;

EID: 51049119400     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.01.017     Document Type: Article

References (33)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 55 (2005) 74-108
2. CNE. Centro Nacional de Epidemiología. Defunciones según la causa de muerte en España. http://cne.isciii.es; 2004.
3. Tardon A., Lee W.J., Delgado-Rodriguez M., Dosemeci M., Albanes D., Hoover R., et al. Leisure-time physical activity and lung cancer: a meta-analysis. Cancer Causes Control 16 (2005) 389-397
4. Rodriguez V., Tardon A., Kogevinas M., Prieto C.S., Cueto A., Garcia M., et al. Lung cancer risk in iron and steel foundry workers: a nested case control study in Asturias, Spain. Am J Ind Med 38 (2000) 644-650
5. Shivapurkar N., Reddy J., Chaudhary P.M., and Gazdar A.F. Apoptosis and lung cancer: a review. J Cell Biochem 88 (2003) 885-898
6. Thomas M., Kalita A., Labrecque S., Pim D., Banks L., and Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19 (1999) 1092-1100
7. Boltze C., Roessner A., Landt O., Szibor R., Peters B., and Schneider-Stock R. Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma. Int J Oncol 21 (2002) 1151-1154
8. Chen Y.C., Xu L., Guo Y.L., Su H.J., Smith T.J., Ryan L.M., et al. Polymorphisms in GSTT1 and p53 and urinary transitional cell carcinoma in south-western Taiwan: a preliminary study. Biomarkers 9 (2004) 386-394
9. Kiyohara C., Otsu A., Shirakawa T., Fukuda S., and Hopkin J.M. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 37 (2002) 241-256
10. Roh J.W., Kim J.W., Park N.H., Song Y.S., Park I.A., Park S.Y., et al. p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol Oncol 93 (2004) 499-505
11. Lai K.C., Chen W.C., Tsai F.J., Li S.Y., and Jeng L.B. Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology 52 (2005) 944-948
12. Popanda O., Edler L., Waas P., Schattenberg T., Butkiewicz D., Muley T., et al. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms. Lung Cancer 55 (2007) 25-34
13. Othayon T., G-BR, Papa M.Z., Distelman M.T., Eisenberg B.S., and Friedman E. The R72P P53 mutation is associated with familial breast cancer in Jewsih women. Br J Cancer 92 (2005) 1144-1148
14. Wu X., Zhao H., Amos C.I., Shete S., Makan N., Hong W.K., et al. p53 genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 94 (2002) 681-690
15. Matakidou A., Eisen T., and Houlston R.S. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18 (2003) 377-385
16. Marín M.S., López-Cima M.F., García-Castro L., Pascual T., Marrón M.G., and Tardón A. Poly (AT) polymorphism in intron 11 of the XPC DNA repair gene enhances the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 13 (2004) 1788-1793
17. Lopez-Cima M.F., Gonzalez-Arriaga P., Garcia-Castro L., Pascual T., Marron M.G., Puente X.S., et al. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of Northern Spain. BMC Cancer 7 (2007) 162
18. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
19. Wolf F.M. Meta-analysis: quantitative methods for research synthesis (1986), Sage Publications, Beverly Hills
20. Campbell C.D., Ogburn E.L., Lunetta K.L., Lyon H.N., Freedman M.L., Groop L.C., et al. Demonstrating stratification in a European American population. Nat Genet 37 (2005) 868-872
21. Pim D., and Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 108 (2004) 196-199
22. Siddique M., and Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 25 (2006) 3489-3500
23. Dumont P., Leu J.I., Della Pietra III A.C., George D.L., and Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33 (2003) 357-365
24. Szymanowska A., Jassem E., Dziadziuszko R., Borg A., Limon J., Kobierska-Gulida G., et al. Increased risk of non-small cell lung cancer and frequency of somatic TP53 gene mutations in Pro72 carriers of TP53 Arg72Pro polymorphism. Lung Cancer 52 (2006) 9-14
25. Mechanic L.E., Marrogi A.J., Welsh J.A., Bowman E.D., Khan M.A., Enewold L., et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 26 (2005) 597-604
26. Hu Y., McDermott M.P., and Ahrendt S.A. The p53 codon 72 proline allele is associated with p53 gene mutations in non-small cell lung cancer. Clin Cancer Res 11 (2005) 2502-2509
27. Schabath M.B., Wu X., Wei Q., Li G., Gu J., and Spitz M.R. Combined effects of the p53 and p73 polymorphisms on lung cancer risk. Cancer Epidemiol Biomarkers Prev 15 (2006) 158-161
28. Sakiyama T., Kohno T., Mimaki S., Ohta T., Yanagitani N., Sobue T., et al. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI REV1 and LIG4 with lung cancer risk. Int J Cancer 114 (2005) 730-737
29. Zhang X., Miao X., Guo Y., Tan W., Zhou Y., Sun T., et al. Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27 (2006) 110-117
30. Liu G., Miller D.P., Zhou W., Thurston S.W., Fan R., Xu L.L., et al. Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma. Cancer Res 61 (2001) 8718-8722
31. Fan R., Wu M.T., Miller D., Wain J.C., Kelsey K.T., Wiencke J.K., et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 9 (2000) 1037-1042
32. Vineis P., Esteve J., Hartge P., Hoover R., Silverman D.T., and Terracini B. Effects of timing and type of tobacco in cigarette-induced bladder cancer. Cancer Res 48 (1988) 3849-3852
33. Fischer S., Spiegelhalder B., and Preussmann R. Preformed tobacco-specific nitrosamines in tobacco-role of nitrate and influence of tobacco type. Carcinogenesis 10 (1989) 1511-1517